|Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341 in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the receptor.
|Structure of the gene for human beta 2-adrenergic receptor: expression and promoter characterization.
|Site-directed mutagenesis and continuous expression of human beta-adrenergic receptors. Identification of a conserved aspartate residue involved in agonist binding and receptor activation.
|cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor.
|Cloning and sequence analysis of the human brain beta-adrenergic receptor. Evolutionary relationship to rodent and avian beta-receptors and porcine muscarinic receptors.
|Primary structure of the human beta-adrenergic receptor gene.
|Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions.
|Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype.
|Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors.
|Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.
|Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects.
|Mutation of tyrosine-141 inhibits insulin-promoted tyrosine phosphorylation and increased responsiveness of the human beta 2-adrenergic receptor.
|Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated by phosphorylation/dephosphorylation of beta-arrestin1.
|Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes.
|A kinase-regulated PDZ-domain interaction controls endocytic sorting of the beta2-adrenergic receptor.
|The palmitoylation state of the beta(2)-adrenergic receptor regulates the synergistic action of cyclic AMP-dependent protein kinase and beta-adrenergic receptor kinase involved in its phosphorylation and desensitization.
|Beta2-adrenergic receptor allele frequencies in the Quechua, a high altitude native population.
|Modulation of postendocytic sorting of G protein-coupled receptors.
|Complete sequencing and characterization of 21,243 full-length human cDNAs.
|The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
|ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.
|Crystal structure of the human beta2 adrenergic G-protein-coupled receptor.
|High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.
|A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor.
|The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor recycling and resensitization.
|Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL.
|Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to mediate ubiquitination of the beta2-adrenergic receptor.
|SNX27 mediates PDZ-directed sorting from endosomes to the plasma membrane.
|SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking of signalling receptors.
|CNIH4 interacts with newly synthesized GPCR and controls their export from the endoplasmic reticulum.
|Insights into beta2-adrenergic receptor binding from structures of the N-terminal lobe of ARRDC3.